Evidence map›Paper›PMID 37000482›Full record

ReviewInteractive journal of medical research2023

Nondrug Intervention for Opportunistic Infections in Individuals With Hematological Malignancy: Systematic Review.

Nor Asiah Muhamad, Nur Hasnah Ma'amor, Normi Mustapha, Fatin Norhasny Leman, Izzah Athirah Rosli, Marilyn Umar, Tahir Aris, Nai Ming Lai

Open access · goldAbstract readReview
In one paragraph

Review in Interactive journal of medical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 76% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Nor Asiah Muhamad *Sector for Evidence-based Healthcare, National Institutes of Health, Ministry of Health, Shah Alam, Malaysia.ORCID https://orcid.org/0000-0002-7772-2103
Nur Hasnah Ma'amorSector for Evidence-based Healthcare, National Institutes of Health, Ministry of Health, Shah Alam, Malaysia.ORCID https://orcid.org/0000-0001-6440-1725
Normi MustaphaFaculty Science and Technology, Open University, Kuala Lumpur, Malaysia.ORCID https://orcid.org/0000-0001-6432-036X
Fatin Norhasny LemanSector for Evidence-based Healthcare, National Institutes of Health, Ministry of Health, Shah Alam, Malaysia.ORCID https://orcid.org/0000-0001-7329-8571
Izzah Athirah RosliSector for Evidence-based Healthcare, National Institutes of Health, Ministry of Health, Shah Alam, Malaysia.ORCID https://orcid.org/0000-0002-6501-8565
Marilyn UmarNon-Communicable Disease Section, Sarawak State Health Department, Ministry of Health, Sarawak, Malaysia.ORCID https://orcid.org/0000-0001-7788-3030
Tahir ArisDirector's Office, Institutes for Medical Research, National Institutes of Health, Ministry of Health, Shah Alam, Malaysia.ORCID https://orcid.org/0000-0002-0205-3080
Nai Ming LaiSchool of Medicine, Faculty of Health & Medical Sciences, Taylor's University, Subang Jaya, Malaysia.ORCID https://orcid.org/0000-0002-4204-3098
Ministry of Health · MYOpen University Malaysia · MYTaylor's University · MY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHematological malignancies disturb the blood, lymph nodes, and bone marrow. Taking medications for treating opportunistic infections (OIs) in these individuals may enhance the risk of medication interaction as well as adverse drug reactions.

objectiveThis review aims to evaluate the effectiveness of nondrug interventions in reducing OIs among patients with hematological cancers.

methodsThe PubMed, CENTRAL (Cochrane Central Register of Controlled Trials), and Embase databases were searched on December 26, 2022, for all randomized controlled trials (RCTs). The primary endpoint was OIs. The quality of included studies was assessed by the Cochrane Risk-of-Bias tool.

resultsA total of 6 studies were included in this review with 4 interventions: (1) types of mouthwash received, (2) presence of coating on central venous catheters (CVCs), (3) use of well-fitted masks, and (4) types of diet consumed. The results were presented in 8 different comparisons: (1) chlorhexidine-nystatin versus saline mouth rinse, (2) chlorhexidine versus saline mouth rinse, (3) nystatin versus saline mouth rinse, (4) chlorhexidine silver sulfadiazine-coated CVCs versus uncoated catheters, (5) well-fitted masks versus no mask, (6) amine fluoride-stannous fluoride versus sodium fluoride mouthwash, (7) low-bacterial diet versus standard hospital diet, and (8) herbal versus placebo mouthwash. No clear differences were reported in any of the outcomes examined in the first 3 comparisons. There were also no clear differences in the rate of catheter-related bloodstream infection or insertion site infection between the use of chlorhexidine silver sulfadiazine-coated CVCs versus uncoated catheters in the patients. Further, no significant differences were seen between patients who used a well-fitted mask and those without a mask in the incidence of OI. The all-cause mortality and mortality due to OI were similar between the 2 groups. There was no clear difference in all-cause mortality, although common adverse effects were reported in patients who used sodium fluoride mouthwash compared with those using amine fluoride-stannous fluoride mouthwash. There was no evidence of any difference in the incidence of possible invasive aspergillosis or candidemia between patients who consumed a low-bacterial diet and a standard diet. For the last comparison, no significant difference was seen between patients who received herbal and placebo mouthwash.

conclusionsVery limited evidence was available to measure the effectiveness of nondrug interventions in hematological cancers. The effectiveness of the interventions included in this review needs to be evaluated further in high-quality RCTs in a dedicated setting among patients with hematological malignancies.

trial registrationPROSPERO International Prospective Register of Systematic Reviews CRD42020169186; https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=169186.

Indexed as

hematological malignanciesinterventionnondrugopportunistic infection

Identifiers

PMID37000482
PMCPMC10132047
OpenAlexW4362473070

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.